Ono Pharmaceutical: revenue fell on Forxiga, but core operating profit rose
Ono Pharmaceutical reported FY2026 Q2 revenue down 9.6% after FORXIGA co-promotion ended, while core operating profit rose 5.1% on royalties and lower costs.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Ono Pharmaceutical reported a 9.6% drop in revenue for the second quarter of FY2026. The decline came as the co-promotion of FORXIGA ended. The information is based on a report published by TradingView.
Core operating profit, however, rose 5.1%. The company attributed this to higher royalty income and lower expenses.
Full-year guidance was left unchanged. The company still expects both revenue and core profit to fall compared with the previous year.
why it matters
The story is mainly relevant to investors in the Japanese drugmaker's shares. A falling top line alongside an expected annual profit decline points to pressure on the core business, but higher royalties and cost savings suggest the company is trying to offset the loss of co-promotion income.
tags
instruments
sources
- Ono Pharmaceutical : FORXIGA drove lower revenue, while royalties and cost savings lifted core profit — TradingView, 29 October 2026 at 07:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗